Join Chemomab for a virtual KOL event, featuring Chris Bowlus, MD (UC Davis Health), Ricky Safer (PSC Partners Seeking a Cure), and Massimo Pinzani, MD, PhD, (UCL, UCL Institute for Liver and Digestive Health, UPMC ISMETT) who will provide clinician and patient perspectives on primary sclerosing cholangitis (PSC), a devastating rare liver disease with no FDA-approved therapies. They will discuss the urgent need for new PSC therapies and emerging scientific and regulatory trends that could facilitate new drug approvals.

The event will include remarks by Chemomab’s Co-founder, CEO & CSO Adi Mor, PhD and CMO Matt Frankel, MD, who will provide an overview of the CM-101 Phase 2 PSC clinical trial that will report topline results midyear 2024. CM-101 is a dual mechanism first-in-class monoclonal antibody that neutralizes CCL24, a soluble protein that is a key driver of inflammatory and fibrotic pathways central to PSC and other fibro-inflammatory diseases.

A live Q&A session will follow the presentations.